---
schema_version: "secwatch.filing_event.v1"
accession: "0001964738-26-000005"
form_type: "8-K"
ticker: "SOLV"
cik: "0001964738"
company_name: "Solventum Corp"
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:49:40.502122+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Solventum reports Q4 2025 sales $2B, organic sales +3.5%; full-year adjusted EPS $6.11, down 8.8% YoY

## Summary
- Q4 reported sales $1,998M (-3.7% YoY); organic sales +3.5% driven by MedSurg and Dental.
- GAAP diluted EPS $0.36; adjusted diluted EPS $1.57 (+11.3% YoY).
- Full-year 2025 adjusted EPS $6.11 (down 8.8% from $6.70); free cash flow -$10M vs $805M in 2024.
- Introduced 2026 full-year guidance for organic sales growth, adjusted EPS, and free cash flow.
- CEO Bryan Hanson: full-year 2025 results ahead of expectations; solid progress toward long-range plan.

## SEC filing metadata
- accession: 0001964738-26-000005
- form_type: 8-K
- ticker: SOLV
- cik: 0001964738
- company_name: Solventum Corp
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1964738/000196473826000005/0001964738-26-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1964738/000196473826000005/solv-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001964738-26-000005
- JSON: https://secwatch.observer/filing/0001964738-26-000005.json
- Plain text: https://secwatch.observer/filing/0001964738-26-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.